Cargando…

A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY

BACKGROUND: Risankizumab (RZB), an anti-IL-23 p19 inhibitor, was well-tolerated and superior to placebo (PBO) in inducing clinical remission and endoscopic response in patients (pts) with moderate-to-severe Crohn’s disease (CD) in two phase 3 studies at 12 weeks. AIMS: FORTIFY (NCT03105102), was a 5...

Descripción completa

Detalles Bibliográficos
Autores principales:	Panaccione, R, Ferrante, M, Feagan, B G, Sandborn, W, Panes, J, Peyrin-Biroulet, L, Colombel, J, Schreiber, S, Dubinsky, M, Baert, F, Hisamatsu, T, Neimark, E, Huang, B, Liao, X, Song, A, Berg, S, Duan, W, Pang, Y, Pivorunas, V, Kligys, K, Wallace, K, D’Haens, G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Poster of Distinction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859234/ http://dx.doi.org/10.1093/jcag/gwab049.036

Ejemplares similares

A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
por: Panaccione, R, et al.
Publicado: (2022)

Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn’s Disease
por: Dubinsky, Marla, et al.
Publicado: (2023)

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn’s Disease: Results from the Phase 2 Open-Label Extension Study
por: Ferrante, Marc, et al.
Publicado: (2021)

Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn’s Disease: A Post Hoc Analysis From the CALM Study
por: Reinisch, Walter, et al.
Publicado: (2020)

Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease
por: Loftus, Edward V., et al.
Publicado: (2023)

A58 CHARACTERIZATION OF THE 37/67 KDA LAMININ RECEPTOR IN COLORECTAL CANCER CELLS
por: Cloutier, G, et al.
Publicado: (2022)

A52 SEX DIFFERENCES IN POST-INFLAMMATORY VISCERAL PAIN IN A MOUSE MODEL OF INFLAMMATORY BOWEL DISEASE (IBD)
por: Arzamendi, M, et al.
Publicado: (2023)

A118 UPPER GASTROINTESTINAL HEMORRHAGE SECONDARY TO SUPERIOR MESENTERIC ARTERY PSEUDOANEURYSM: CASE REPORT AND REVIEW OF LITERATURE
por: Guo, H, et al.
Publicado: (2022)

A37 FECAL CALPROTECTIN IN A PEDIATRIC, POPULATION-BASED STUDY: UTILITY IN DIAGNOSIS AND INFLAMMATORY BOWEL DISEASE MONITORING
por: Smyth, M, et al.
Publicado: (2023)

A52 GUT-INNERVATING TRPV1+ NEURONS DRIVE CHRONIC VISCERAL PAIN VIA MICROGLIAL P2Y12 RECEPTOR
por: Defaye, M, et al.
Publicado: (2022)

A87 HEALTHCARE PROVIDER SATISFACTION WITH VIRTUAL CARE DELIVERY IN ALBERTA DURING THE COVID-19 PANDEMIC.
por: Olayinka, L, et al.
Publicado: (2021)

A73 CANADIAN INFLAMMATORY BOWEL DISEASE MOBILE APPS: CURRENT LANDSCAPE AND NEEDS
por: Chiew, B A, et al.
Publicado: (2022)

A phase II study of laquinimod in Crohn's disease
por: D'Haens, Geert, et al.
Publicado: (2015)

A31 MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY-TO-SEVERELY ACTIVE UC: IMPROVEMENT IN IBDQ SCORES IN PARTICIPANTS OF LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALS
por: Sands, B E, et al.
Publicado: (2023)

A42 HETEROGENEITY IN EFFICACY AND SAFETY ENDPOINTS FOR PEDIATRIC CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE: A NEED FOR HARMONIZATION
por: Crowley, E, et al.
Publicado: (2022)

A236 ASSOCIATION OF STOOL METABOLOMIC PROFILE AND MICROBIOME COMPOSITION RISK SCORE WITH FUTURE ONSET OF CROHN’S DISEASE
por: Lee, S, et al.
Publicado: (2022)

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
por: Panés, Julian, et al.
Publicado: (2017)

A54 DIETARY COMPONENTS ARE ASSOCIATED WITH FECAL CALPROTECTIN IN ULCERATIVE COLITIS
por: Chiu, E, et al.
Publicado: (2022)

A158 COMPARING CORTIMENT® AND PREDNISONE IN ULCERTATIVE COLITIS: A POPULATION-BASED STUDY OF OUTCOMES
por: Coward, S, et al.
Publicado: (2022)

A211 INCIDENCE OF PRIMARY SCLEROSING CHOLANGITIS: A META-ANALYSIS OF POPULATION-BASED STUDIES
por: Cooper, J, et al.
Publicado: (2022)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

A173 INNOVATIVE CARE FOR INFLAMMATORY BOWEL DISEASE PATIENTS DURING THE COVID-19 PANDEMIC: USE OF BEDSIDE INTESTINAL ULTRASOUND TO OPTIMIZE MANAGEMENT
por: Novak, K L, et al.
Publicado: (2021)

A97 DEVELOPMENT OF PREDICTION MODELS FOR THE TRIAGING OF REFERRALS OF INDIVIDUALS WITH SUSPECTED INFLAMMATORY BOWEL DISEASE TO IMPROVE PROMPT ACCESS TO CARE
por: St-Pierre, J, et al.
Publicado: (2022)

Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review
por: Colombel, Jean-Frédéric, et al.
Publicado: (2020)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

A35 FORECASTING THE INCIDENCE AND PREVALENCE OF INFLAMMATORY BOWEL DISEASE: A CANADIAN NATION-WIDE ANALYSIS
por: Coward, S, et al.
Publicado: (2023)

Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy
por: Colombel, J.‐F., et al.
Publicado: (2016)

Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
por: Panaccione, Remo, et al.
Publicado: (2020)

A157 DEFINITIONS OF MEDITERRANEAN DIET INCONSISTENTLY ASSOCIATE WITH MARKERS OF GUT BARRIER FUNCTION OR SUBCLINICAL INFLAMMATION IN A POPULATION-BASED COHORT
por: Neustaeter, A, et al.
Publicado: (2022)

Risankizumab shows high efficacy and maintenance in improvement of response until week 52
por: Mastorino, Luca, et al.
Publicado: (2022)

Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn’s Disease
por: Sandborn, William J, et al.
Publicado: (2021)

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience
por: Caldarola, Giacomo, et al.
Publicado: (2023)

Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52
por: Johnson, Travis, et al.
Publicado: (2023)

Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2021)

Risankizumab for psoriasis
Publicado: (2020)

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme
por: Sandborn, William J, et al.
Publicado: (2022)

Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials
por: Panaccione, Remo, et al.
Publicado: (2018)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Ustekinumab improves health‐related quality of life in patients with moderate‐to‐severe Crohn's disease: Results up to Week 104 of the STARDUST trial
por: Panés, Julian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3lttao434jv4glmj6uoc8m2sma